# MAGNETISMM-5 (NCT05020236)

> A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05020236
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab; Daratumumab; Pomalidomide; Dexamethasone
- Enrollment: 893
- Primary outcome: Part 1 Safety Lead-In: Incidence of dose limiting toxicities
- Primary outcome: Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria
- Primary outcome: Part 3: Frequency of treatment-emergent adverse events

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 15
- YouTube: 9
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=magnetismm-5-nct05020236

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05020236", "email": "<work email>"}; the inbox owner confirms by the emailed link.